Investment Rating - The report maintains a "Buy" rating for Yingkang Life (300143) [1] Core Views - The company achieved a total revenue of 1.471 billion yuan in 2023, representing a year-on-year growth of 27.20%, and a net profit attributable to shareholders of 100.44 million yuan, up 116.85% year-on-year [1] - The medical device segment has shown rapid growth, with revenue reaching 322 million yuan in 2023, a year-on-year increase of 101.69%, supported by acquisitions and continuous investment in R&D [2] - The medical services segment also performed well, with revenue of 1.149 billion yuan in 2023, a year-on-year increase of 15.28%, and a surgical volume increase of 20% [12] Financial Forecasts and Valuation - The company forecasts total revenue for 2024 to be 1.827 billion yuan, with a projected net profit of 144 million yuan, reflecting a growth rate of 43% [13] - The estimated P/E ratios for 2024, 2025, and 2026 are 36, 27, and 22 respectively, indicating a favorable valuation as the company enters a phase of accelerated profit growth [13] - The operating cash flow for 2023 was 190 million yuan, with expectations of continued improvement in cash flow management [7]

| | | 二、前次募集资金使用情况报告 和信会计师事务所（特殊普通合伙） 二〇二四年四月二十五日 盈康生命科技股份有限公司 鉴证报告 盈康生命科技股份有限公司 截至 2024 年 3 月 31 日 前次募集资金使用情况鉴证报告 和信专字（2024）第 000261 号 和信专字（2024）第 000261 号 盈康生命科技股份有限公司全体股东： 我们鉴证了后附的盈康生命科技股份有限公司（以下简称"盈康生命"）董事 会编制的《截至 2024 年 3 月 31 日止前次募集资金使用情况报告》（以下简称"专 项报告"）。 一、盈康生命董事会的责任 盈康生命董事会的责任是按照中国证券监督管理委员会发布的《监管规则适 用指引-发行类第 7 号》的相关规定编制专项报告。这种责任包括设计、执行和维 护与募集资金专项报告编制相关的内部控制，确保募集资金专项报告真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对专项报告发表鉴证结论。我们按照 《中国注册会计师其他鉴证业务准则第 3101 号-历史财务信息审计或审阅以外的 鉴证业务》的规定执行了鉴证工作。该准则 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于2024年4月22日以电话、 邮件方式向全体监事发出召开公司第六届监事会第七次（临时）会议的通知。本 次会议于2024年4月25日在山东省青岛市崂山区海尔路一号盈康一生大厦19楼董事 会议室以现场的方式召开。会议应出席监事 3 人，实际出席监事 3 人，监事龚雯 雯、王旭东、李超峰以现场方式出席会议并投票表决。本次会议由监事会主席龚 雯雯女士主持，公司部分高级管理人员列席了会议。 证券代码：300143 证券简称：盈康生命 公告编号：2023-028 盈康生命科技股份有限公司 第六届监事会第七次（临时）会议决议公告 根据中国证券监督管理委员会颁布的《监管规则适用指引——发行类第7号》， 公司编制了《盈康生命科技股份有限公司截至2024年3月31日止前次募集资金使用 情况报告》。 具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《盈康生 命科技股份有限公司截至2024年3月31日止前次募集资金使用情况报告》。 本次会议 ...

证券代码：300143 证券简称：盈康生命 公告编号：2024-030 盈康生命科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）根据中华人民共和国财政部 （以下简称"财政部"）印发的相关规定变更相应的会计政策，具体变更情况如下： 一、本次会计政策变更的概述 （一）变更原因 本次会计政策变更后，公司按照财政部颁布的 17 号准则解释相关规定执行。 除上述会计政策变更外，其他未变更部分仍按照财政部前期颁布的《企业会计准则 ——基本准则》和相关具体准则、企业会计准则应用指南、企业会计准则解释及其 他相关规定执行。 1 （四）变更日期 公司自上述文件规定的适用日期开始执行变更后的会计政策。 二、本次会计政策变更的主要内容 根据《企业会计准则解释第 17 号》的要求，会计政策变更的主要内容如下： 2023 年 10 月 25 日，财政部颁布了《企业会计准则解释第 17 号》（财会〔2023〕 21 号，以下简称"17 号准则解释"），其中"关于流动负债与非流动负债的划分""关 于供应商 ...

盈康生命科技股份有限公司截至 2024 年 3 月 31 日止前次募集资金使用情况报告 （本报告除特别注明外，均以人民币元列示） 盈康生命科技股份有限公司 截至2024年3月31日止 前次募集资金使用情况报告 盈康生命科技股份有限公司（以下简称"本公司"或"公司"）董事会根据中国证券 监督管理委员会发布的《监管规则适用指引-发行类第7号》，编制了本公司于2020年7月 募集的人民币普通股资金截至2024年3月31日止的使用情况报告（以下简称前次募集资金 使用情况报告）。本公司董事会保证前次募集资金使用情况报告的内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏。 一、前次募集资金情况 经中国证券监督管理委员会《关于核准盈康生命科技股份有限公司非公开发行股票的 批复》（证监许可[2020]1030 号）核准，公司向特定对象青岛盈康医疗投资有限公司非 公开发行人民币普通股（A 股）96,312,746 股，每股面值为人民币 1 元，每股发行价格为 人民币 7.61 元。本次发行募集资金总额为人民币 732,939,997.06 元，扣除各项发行费用 （不含税）人民币 5,051,786.18 元后，实际 ...

证券代码：300143 证券简称：盈康生命 公告编号：2024-027 盈康生命科技股份有限公司 第六届董事会第八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第八次（临时）会议的通知。会议 于 2024 年 4 月 25 日在山东省青岛市崂山区海尔路一号盈康一生大厦 19 楼董事会议 室以现场结合通讯的方式召开。会议应出席董事 7 人，实际出席董事 7 人，董事谭 丽霞、彭文以现场方式出席会议并投票表决，董事潘绵顺、沈旭东、独立董事杜媛、 独立董事姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本次会议由董事长 谭丽霞女士主持，公司的监事、高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公司 章程》及有关法律、法规的规定。 1 表决结果：同意 7 票，反对 0 票，弃权 0 票。 （二）审议通过《关于前次募集资金使用情况的议案》 根据 ...

[Key Financial Data](index=1&type=section&id=Item%20I.%20Key%20Financial%20Data) The company's Q1 2024 revenue grew by **15.17%** to **RMB 416 million**, while net profit attributable to shareholders decreased by **33.69%** to **RMB 26.23 million**, despite strong operating cash flow growth of **164.52%** to **RMB 102 million** [Key Accounting Data and Financial Indicators](index=1&type=section&id=(I)%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2024, the company achieved operating revenue of **RMB 416 million**, a **15.17%** year-over-year increase, while net profit attributable to shareholders significantly decreased by **33.69%** to **RMB 26.23 million**, despite operating cash flow reaching **RMB 102 million**, up **164.52%** Key Financial Indicators for Q1 2024 | Indicator | Current Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 416,230,884.39 | 361,417,574.60 | +15.17% | | Net Profit Attributable to Parent (RMB) | 26,225,857.82 | 39,550,000.16 | -33.69% | | Non-recurring Net Profit Attributable to Parent (RMB) | 23,824,607.82 | 38,768,280.17 | -38.55% | | Net Cash Flow from Operating Activities (RMB) | 102,289,209.00 | 38,669,216.63 | +164.52% | | Basic Earnings Per Share (RMB/share) | 0.0410 | 0.0616 | -33.44% | Key Balance Sheet Indicators at Period-End | Indicator | End of Current Period | End of Prior Year | Period-end vs Prior Year-end Change | | :--- | :--- | :--- | :--- | | Total Assets (RMB) | 2,521,874,590.97 | 2,400,229,493.43 | +5.07% | | Equity Attributable to Shareholders of Listed Company (RMB) | 1,367,642,669.70 | 1,381,668,862.20 | -1.02% | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=(II)%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **RMB 2.40 million**, primarily comprising government grants of **RMB 3.03 million** and net other non-operating income/expenses of **-RMB 0.23 million**, with software VAT refunds of **RMB 1.01 million** classified as recurring income Details of Non-Recurring Gains and Losses Items | Item | Amount for Current Period (RMB) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | 226,466.75 | | Government Grants Recognized in Current P&L | 3,028,683.79 | | Other Non-operating Income and Expenses | -458,029.41 | | **Total** | **2,401,250.00** | - The company classified **RMB 1.01 million** in software VAT refunds, closely related to normal operations, as recurring gains and losses, not non-recurring items[7](index=7&type=chunk) [Analysis of Changes in Key Financial Indicators](index=3&type=section&id=(III)%20Analysis%20of%20Changes%20in%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Key financial indicators showed significant fluctuations this period, with net profit attributable to parent decreasing by **33.69%** primarily due to increased equity incentive expenses, while net cash flow from operating activities surged by **164.52%** driven by the healthcare services segment - Net profit attributable to shareholders and non-recurring net profit attributable to shareholders decreased by **33.69%** and **38.55%** year-over-year, respectively, primarily due to increased equity incentive expenses in the current period[8](index=8&type=chunk) - Net cash flow from operating activities significantly increased by **164.52%** year-over-year, mainly due to increased net cash flow from the healthcare services segment in the current period[8](index=8&type=chunk) [Shareholder Information](index=3&type=section&id=Item%20II.%20Shareholder%20Information) As of the reporting period end, the company had **17,088** common shareholders, with the largest shareholder, Qingdao Yingkang Medical Investment Co., Ltd., holding **39.93%** and acting in concert with the second largest shareholder, both controlled by Haier Group [Shareholder Holdings](index=3&type=section&id=(I)%20Total%20Number%20of%20Common%20Shareholders%2C%20Number%20of%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders'%20Holdings) As of the reporting period end, the company had **17,088** common shareholders, with Qingdao Yingkang Medical Investment Co., Ltd. as the largest shareholder holding **39.93%**, acting in concert with the second largest shareholder, both controlled by Haier Group - As of the end of the reporting period, the company had a total of **17,088** common shareholders[9](index=9&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Shareholder Type | Shareholding (%) | Number of Shares Held | | :--- | :--- | :--- | :--- | | Qingdao Yingkang Medical Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 39.93% | 256,446,585 | | Qingdao Haichuangzhi Management Consulting Enterprise (Limited Partnership) | Domestic Non-state-owned Legal Person | 1.73% | 11,104,500 | | Ye Fulin | Domestic Natural Person | 1.70% | 10,922,141 | - The top two shareholders, Qingdao Yingkang Medical Investment Co., Ltd. and Qingdao Haichuangzhi Management Consulting Enterprise (Limited Partnership), are parties acting in concert with the company's actual controller, Haier Group Corporation[10](index=10&type=chunk) [Changes in Restricted Shares](index=4&type=section&id=(III)%20Changes%20in%20Restricted%20Shares) During the reporting period, the company's total restricted shares decreased by **13,500** due to the unlocking of executive restricted shares, involving two executives, He Ling and Liu Gang, both with zero restricted shares at period-end Details of Restricted Share Changes | Shareholder Name | Restricted Shares at Beginning of Period | Restricted Shares Released This Period | Restricted Shares at End of Period | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | | He Ling | 7,875 | 7,875 | 0 | Executive Restricted Shares | | Liu Gang | 5,625 | 5,625 | 0 | Executive Restricted Shares | | **Total** | **13,500** | **13,500** | **0** | | [Other Significant Matters](index=5&type=section&id=Item%20III.%20Other%20Significant%20Matters) During the reporting period, the company actively managed its market value by initiating a share repurchase plan of **RMB 40-80 million** for equity incentives or employee stock ownership, while the controlling shareholder increased its stake and plans further purchases within six months, demonstrating confidence in the company's prospects - The company initiated a share repurchase plan in February 2024, intending to use **RMB 40-80 million** of its own funds to repurchase shares; as of March 29, **5,244,152** shares had been repurchased, totaling **RMB 44.86 million**[14](index=14&type=chunk) - The company's controlling shareholder, Qingdao Yingkang Medical Investment Co., Ltd., increased its holdings by **370,000** shares in February 2024 and plans to continue increasing its stake by **RMB 10-20 million** within six months from February 20[15](index=15&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=Item%20IV.%20Quarterly%20Financial%20Statements) The company's Q1 2024 financial statements show total assets increased by **5.07%** to **RMB 2.52 billion**, total liabilities rose by **14.00%** to **RMB 1.11 billion**, and net profit attributable to parent decreased by **33.69%** to **RMB 26.23 million**, while operating cash flow significantly improved to **RMB 102 million** [Consolidated Balance Sheet](index=5&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2024, the company's total assets reached **RMB 2.52 billion**, up **5.07%** from the beginning of the year, while total liabilities increased by **14.00%** to **RMB 1.11 billion**, driven by higher short-term and long-term borrowings, and equity attributable to parent slightly decreased by **1.02%** to **RMB 1.37 billion** Key Balance Sheet Items (Period-end vs Beginning-of-period) | Item | Period-end Balance (RMB) | Beginning-of-period Balance (RMB) | Change | | :--- | :--- | :--- | :--- | | **Total Assets** | **2,521,874,590.97** | **2,400,229,493.43** | **+5.07%** | | Cash and Cash Equivalents | 528,583,505.72 | 480,489,632.31 | +10.01% | | **Total Liabilities** | **1,107,259,115.67** | **971,419,126.24** | **+14.00%** | | Short-term Borrowings | 188,135,722.22 | 168,150,722.22 | +11.89% | | Long-term Borrowings | 72,066,000.00 | 20,040,833.33 | +259.60% | | **Equity Attributable to Parent Company Owners** | **1,367,642,669.70** | **1,381,668,862.20** | **-1.02%** | [Consolidated Income Statement](index=8&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2024, the company's total operating revenue was **RMB 416 million**, a **15.17%** year-over-year increase, but operating profit decreased by **26.90%** to **RMB 34.70 million** due to significant increases in operating costs and administrative expenses (**19.0%**), resulting in net profit attributable to parent of **RMB 26.23 million**, down **33.69%** Key Income Statement Items (Year-over-Year) | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 416,230,884.39 | 361,417,574.60 | +15.17% | | Total Operating Costs | 382,865,011.79 | 313,852,675.18 | +21.99% | | Including: Administrative Expenses | 46,917,988.88 | 39,429,420.07 | +19.00% | | Operating Profit | 34,701,575.17 | 47,469,023.13 | -26.90% | | Net Profit Attributable to Parent Company Owners | 26,225,857.82 | 39,550,000.16 | -33.69% | [Consolidated Cash Flow Statement](index=9&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) During the reporting period, the company maintained a healthy cash flow, with net cash flow from operating activities significantly increasing by **164.52%** to **RMB 102 million**, while net cash outflow from investing activities was **RMB 73.90 million**, and net cash inflow from financing activities was **RMB 20.99 million**, leading to a **RMB 49.40 million** increase in cash and cash equivalents to **RMB 520 million** at period-end Cash Flow Statement Overview | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 102,289,209.00 | 38,669,216.63 | | Net Cash Flow from Investing Activities | -73,896,713.14 | -57,320,837.17 | | Net Cash Flow from Financing Activities | 20,992,988.23 | -1,690,284.22 | | Net Increase in Cash and Cash Equivalents | 49,398,245.13 | -20,494,956.30 |

证券代码：300143 证券简称：盈康生命 公告编号：2024-029 盈康生命科技股份有限公司 关于召开2024年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《公司章程》的有关规定，经盈康生命科技股 份有限公司（以下简称"公司"）第六届董事会第八次（临时）会议审议通过，决 定于2024年5月15日召开公司2024年第二次临时股东大会，现将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024年第二次临时股东大会。 2、股东大会的召集人：公司董事会。 3、会议召开的合法、合规性：本次股东大会的召集、召开程序符合有关法律、 行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》的 规定。 4、会议召开的日期、时间： （1）现场会议时间：2024年5月15日（星期三）14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为2024年5月15日的交易时间，即9:15-9:25，9:30-11:30和13:00-15:00；通过深圳证 券交易所互联网投票 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][10]. Core Insights - The company has demonstrated robust growth in its medical services and successful integration in the medical device sector, with hospital business revenue reaching 1.15 billion yuan in 2023, a year-on-year increase of 15.3% [1]. - The medical device segment achieved revenue of 322 million yuan, reflecting a significant year-on-year growth of 101.7%, primarily driven by the consolidation of Shenzhen Saintno [1][2]. - The company is expected to continue its steady growth trajectory, supported by improved operational quality in hospitals and ongoing enhancements in the medical device segment [2]. Summary by Sections Revenue Performance - The company reported a total revenue of 1.47 billion yuan in 2023, representing a year-on-year increase of 27.2% [7]. - The net profit for 2023 was 100 million yuan, a substantial increase of 116.85% year-on-year [7]. Financial Projections - The forecast for net profit for 2024 and 2025 has been adjusted to 126 million yuan and 157 million yuan, respectively, reflecting a downward revision of 32% and 40% from previous estimates [2]. - The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.20 yuan, 0.24 yuan, and 0.30 yuan, with corresponding price-to-earnings (P/E) ratios of 39, 32, and 25 [2]. Operational Developments - The company is actively advancing the construction of regional medical centers, enhancing its diagnostic and treatment capabilities [6]. - The focus on oncology services has led to a comprehensive product line covering key treatment scenarios, with ongoing efforts to strengthen market presence through strategic acquisitions [6].

Summary of Conference Call Company/Industry Involved - The conference call pertains to Huazhong Securities Research Institute, specifically addressing its whitelist clients [1] Core Points and Arguments - The call emphasizes that it does not constitute investment advice for participants [1] - Participants are reminded to make independent investment decisions and bear their own investment risks [1] - Huazhong Securities disclaims any responsibility for losses incurred by individuals using the content of the meeting [1] Other Important but Possibly Overlooked Content - The call is governed by the Securities and Futures Investor Suitability Management Measures, indicating regulatory compliance [1]